image
Healthcare - Biotechnology - NASDAQ - US
$ 1.545
6.25 %
$ 87.4 M
Market Cap
-1.34
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TCRX stock under the worst case scenario is HIDDEN Compared to the current market price of 1.54 USD, TScan Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TCRX stock under the base case scenario is HIDDEN Compared to the current market price of 1.54 USD, TScan Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TCRX stock under the best case scenario is HIDDEN Compared to the current market price of 1.54 USD, TScan Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TCRX

image
$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
2.82 M REVENUE
-86.62%
-135 M OPERATING INCOME
-44.26%
-127 M NET INCOME
-42.91%
-111 M OPERATING CASH FLOW
-80.62%
-52.6 M INVESTING CASH FLOW
13.41%
209 M FINANCING CASH FLOW
54.13%
665 K REVENUE
-36.61%
-36.7 M OPERATING INCOME
-12.54%
-35.8 M NET INCOME
-19.81%
-27.4 M OPERATING CASH FLOW
1.81%
27.3 M INVESTING CASH FLOW
133.14%
45.7 M FINANCING CASH FLOW
3614.63%
Balance Sheet TScan Therapeutics, Inc.
image
Current Assets 293 M
Cash & Short-Term Investments 290 M
Receivables 0
Other Current Assets 2.61 M
Non-Current Assets 78.4 M
Long-Term Investments 0
PP&E 71.6 M
Other Non-Current Assets 6.8 M
78.17 %19.29 %Total Assets$371.1m
Current Liabilities 36 M
Accounts Payable 4.28 M
Short-Term Debt 4.57 M
Other Current Liabilities 27.1 M
Non-Current Liabilities 94.2 M
Long-Term Debt 60.7 M
Other Non-Current Liabilities 33.5 M
3.29 %3.51 %20.83 %46.67 %25.70 %Total Liabilities$130.1m
EFFICIENCY
Earnings Waterfall TScan Therapeutics, Inc.
image
Revenue 2.82 M
Cost Of Revenue 0
Gross Profit 2.82 M
Operating Expenses 138 M
Operating Income -135 M
Other Expenses -7.32 M
Net Income -127 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)3m03m(138m)(135m)7m(127m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-4787.68% OPERATING MARGIN
-4787.68%
-4527.66% NET MARGIN
-4527.66%
-52.91% ROE
-52.91%
-34.36% ROA
-34.36%
-39.68% ROIC
-39.68%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis TScan Therapeutics, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)202020202021202120222022202320232024202420252025
Net Income -127 M
Depreciation & Amortization 4.11 M
Capital Expenditures -3.82 M
Stock-Based Compensation 9.55 M
Change in Working Capital 5.05 M
Others 1.03 M
Free Cash Flow -115 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets TScan Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for TCRX of $7.5 , with forecasts ranging from a low of $3 to a high of $12 .
TCRX Lowest Price Target Wall Street Target
3 USD 94.17%
TCRX Average Price Target Wall Street Target
7.5 USD 385.44%
TCRX Highest Price Target Wall Street Target
12 USD 676.70%
Price
Max Price Target
Min Price Target
Average Price Target
121210108866442200Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership TScan Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
952 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
391 K USD 1
3-6 MONTHS
82.6 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time. globenewswire.com - 1 month ago
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience globenewswire.com - 1 month ago
TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barring positive feedback from regulatory authorities, the company hopes to develop TSC-101 for AML, MDS, ALL patients who undergo HSCT in a pivotal study in the 2nd half of 2025. The company is developing multiplex TCR-Ts for treatment of patients with solid tumors, with phase 1 PLEXI-T trial data anticipated in the second half of 2025. seekingalpha.com - 1 month ago
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.21 per share a year ago. zacks.com - 1 month ago
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66 th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-202-A0201 targeting MAGE-A4 on HLA-A*02:01 Closed $30 million registered direct offering at 37% premium with long-standing, supportive shareholder Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2024, and provided a business update. globenewswire.com - 1 month ago
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time. globenewswire.com - 2 months ago
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time. globenewswire.com - 2 months ago
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism. seekingalpha.com - 2 months ago
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com - 3 months ago
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an aggregate of 7,500,000 shares of its voting common stock at a price of $4.00 per pre-funded warrant, each exercisable to purchase one share of voting common stock at an exercise price of $0.0001 per share, representing a premium of 37% to the last closing price of TScan Therapeutics' common stock, and a 34% premium over the 10-day volume weighted average closing price. The financing is expected to close on or about December 27, 2024, subject to customary closing conditions. globenewswire.com - 4 months ago
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 globenewswire.com - 4 months ago
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) globenewswire.com - 4 months ago
8. Profile Summary

TScan Therapeutics, Inc. TCRX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 87.4 M
Dividend Yield 0.00%
Description TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Contact 830 Winter Street, Waltham, MA, 02451 https://www.tscan.com
IPO Date July 16, 2021
Employees 194
Officers Dr. Zoran Zdraveski J.D., Ph.D. Chief Legal & Strategy Officer and Company Secretary Dr. Chrystal U. Louis M.D., M.P.H. Chief Medical Officer Dr. Shrikanta Chattopadhyay M.D. Senior Vice President & Head of Translational Medicine Dr. Gavin MacBeath Ph.D. Chief Executive Officer & Director Mr. Tomasz Kula Ph.D. Co-Founder & Member of Advisory Board Dr. Justin McCue Ph.D. Chief Technology Officer Ms. Ann Hargraves Senior Vice President of Human Resources Mr. Ray Lockard M.B.A. Senior Vice President & Head of Quality Mr. Jason A. Amello CPA Chief Financial Officer & Treasurer Dr. Stephen J. Elledge Ph.D. Co-Founder & Chairman of Scientific Advisory Board